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ABSTRACT
Introduction Children with primary immunodeficiency
disorders (PID) are more susceptible to developing viral
infections and are at a substantially increased risk of
developing paralytic poliomyelitis. Such children, if given oral
polio vaccines tend to excrete poliovirus chronically that may
lead to the propagation of highly divergent vaccine-derived
poliovirus (VDPV). Consequently, they may act as a reservoir
for the community by introducing an altered virus potentially
imposing a risk to global polio eradication. However, the risks
of chronic and prolonged excretion are not well characterised
in the study context. This study seeks to establish a pilot
surveillance system for successful identification and
monitoring of VDPV excretion among children with PID. It will
assess whether the Jeffrey Modell warning signs of PID can
be used as an appropriate screening tool for PID in Pakistan.
Methods and analysis In this pilot surveillance,
recruitment of PID cases is currently done at participating
hospitals in Pakistan. Potential children are screened
and tested against the Jeffrey Modell Foundation (JMF)
warning signs for immunodeficiency and their stool is
collected to test for poliovirus excretion. Cases excreting
poliovirus are followed until the two consecutive negative
stool samples are obtained over a period of 6 months.
The data will be analysed to calculate hospital-based
proportions of total Immunodeficiency-related vaccine-
derived poliovirus (iVDPV) cases over a 2-year period and
to determine the sensitivity and specificity of the JMF
signs.
Ethics and dissemination This protocol was
reviewed and approved by the WHO (WHO
Reference-2018/811124-0), Aga Khan University (AKU
ERC-2018-0380-1029) and National Bioethics Committee
(Ref No. 4-87 NBC-308-Y2). The results will be published
in an open access peer-reviewed scientific journal and
presented to the iVDPV Working Group members, policy-
makers, paediatric consultants and fellow researchers with
the same domain interest. It may be presented in scientific
conferences and seminars in the form of oral or poster
presentations.

INTRODUCTION
Polio is a highly infectious viral disease which
invades the nervous system of a child and

Strengths and limitations of this study
►► Primary immunodeficiency disorders (PID) patients

are screened for excretion of poliovirus for the first
time in Pakistan.
►► Jeffrey Modell warning signs for PID are used together with immunological diagnostic testing for
PID.
►► Poliovirus excretors are followed up in monthly intervals until two consecutive samples are negative.
►► Proportions and types of poliovirus excretors among
PID patients are analysed monthly.
►► While attempts were made to cover entire Pakistan,
the screening may miss PID cases in more remote
areas.

may cause irreversible paralysis.1 The use
of the live oral poliovirus vaccine (OPV) in
routine and supplementary immunisation
activities has significantly reduced the incidence of paralytic poliomyelitis and transmission of wild polioviruses around the globe.
This success can be attributed to the ability of
this vaccine to induce mucosal immunity as
well as serum neutralising antibodies protective against paralytic poliomyelitis.2 However,
individuals with primary immunodeficiency
disorders (PID) exposed to OPV through
vaccination or household contacts are not
only at increased risk of vaccine-
associated
paralytic poliomyelitis but may also have
prolonged excretion of Sabin vaccine-derived
polioviruses (VDPVs).3 Sabin polioviruses are
known to have increased transmissibility and
neurovirulence following prolonged intestinal replication. Such individuals could theoretically transmit the virus to contacts and the
general population following the interruption of wild poliovirus transmission.4 These
polioviruses are called immunodeficiency-
related vaccine-derived poliovirus (iVDPVs),
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which indicates that these viruses have replicated and
evolved in immunocompromised individuals. Previous
studies in Sri Lanka, Egypt, Bangladesh and elsewhere
demonstrated that it is essential to identify PID persons
excreting polioviruses.1 5 6
Poliovirus excretion into the environment negates
global poliovirus eradication efforts. PID individuals
infected with poliovirus are at risk of developing paralysis. Antiviral therapy will be offered to those identified
immunodeficient children who are excreting polioviruses
to prevent the spread of these polioviruses.
Aim
Identification and diagnosis of PID is complex and requires
specialist interventions. The Jeffrey Modell Foundation
(JMF) has developed 10 warning signs for the screening of
suspected primary immunodeficiency patients.7 Although
this screening tool has been used in various countries, its
sensitivity and specificity in low-resource countries such as
Pakistan have not been assessed. The primary aim of this
project is to develop a pilot surveillance system for the
identification of primary immunodeficient children in
sentinel sites of Pakistan which will provide the basis for
the development of longer-term surveillance structure for
the successful identification, genetic characterisation and
monitoring of VDPV excretion. This will help in identifying long-term poliovirus excretors among them, which
will in return help in the prevention of future transmission and VDPV outbreaks.
Secondary aims will be to calculate the hospital-based
proportion of iVDPV cases and to document the identified iVDPV cases in the WHO global registry list. Finally,
it will help assess whether the Jeffrey Modell warning
signs of PID are an appropriate screening tool for PID in
Pakistan.

Training of master trainers workshop
The master training workshops were conducted all over
the country in collaboration with WHO, Pakistan. All
tertiary care hospitals in each province with paediatricians were approached. Across Pakistan, 49 tertiary care
hospitals have been participating in iVDPV surveillance.
The participatory rate from the province Sindh (n=7)
and Balochistan (n=3) is 100%, followed by 72.5% (n=29)
from the province Punjab. The participatory proportion
from the province Khyber Pakhtunkhwa (n=10) is 38.5%,
which is the lowest among the remaining provinces
(figure 1). The purpose of the training workshop was to
train the master trainers who in turn guided their departmental doctors for screening and identification of PID
children using the JMF warning signs.
The master training workshops were conducted by
the principal investigator (PI) of this project who is a
paediatric infectious diseases consultant at the Aga Khan
University Hospital in collaboration with WHO experts in
Polio Surveillance.
Coordination process
This study requires close collaboration and coordination among the stakeholders. The Aga Khan University
Hospital (Pakistan) is the main coordination centre for
the study. A research coordinator (RC) serves as a liaison
between the participatory hospitals in each province
and the WHO provincial team, which collects the stool
samples of identified PID children. National Institute of
Health, Islamabad virology lab processes the stool samples
and identifies the type of poliovirus.

METHODOLOGY
Project structure
The surveillance of iVDPV is currently being undertaken at participatory tertiary healthcare facilities around
Pakistan. This pilot surveillance will help in structuring
term surveillance for PID children
a sustainable, long-
in Pakistan. In the initial stage, mapping was executed
to identify participatory hospitals and their consultant
paediatricians. Master training workshops were then
conducted for these paediatricians from the selected
hospitals of each province of Pakistan who agreed to
participate in iVDPV surveillance. The project was rolled
out as follows:
►► First 6 months: Aga Khan University (AKU) Hospital+three other major tertiary care hospitals in Karachi
►► Months 7–24: AKU Hospital+major hospitals in Karachi+tertiary hospitals located in the provinces of
Sindh (Hyderabad), Punjab (Lahore, Multan, Islamabad), Balochistan (Quetta), Khyber Pakhtunkhwa
and Gilgit-Baltistan.

Data collection process
Children are identified by the paediatricians trained on
Jeffrey Model Foundation warning signs and the diagnosis of primary immunodeficiency. Any child (up to 18
years of age) fulfilling the criteria of two or more positive JMF signs, will be further assessed and tested for HIV.
The children who test negative for HIV, either suspected
or confirmed PIDs are considered potential iVDPV
excreters and are enrolled in the study. Enrolled children
will be further tested for complete blood count (CBC),
flow cytometry and quantitative measurement of immunoglobulins (QIGs) level after consulting with the coordination cell at the Aga Khan University. A consultant
haematologist at the Aga Khan University will review the
flow cytometry and immunoglobulins level reports. After
enrolment, WHO provincial teams collect two consecutive stool samples, which are examined for poliovirus at
National Institute of Health (NIH) Islamabad-Pakistan
using standard poliovirus detection methodology used in
the Global Polio Laboratory Network. The second stool
sample will be collected 24 hours after the first sample.
Any child found to be positive will be followed up with
monthly stool samples for 6 months or till two subsequent
samples become negative. All iVDPVs detected will be
documented in the WHO global registry list of known
iVDPV cases.
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Figure 1

Participatory tertiary care hospitals. KPK, Khyber Pakhtunkhwa.

Follow-up with the iVDPV cases
The parents or guardians of iVDPV positive children
are informed and followed up closely by Expanded
Programme on Immunization (EPI) and Union Council
teams along with WHO provincial teams. Children
are followed up until two consecutive negative stool
samples for a period of 6 months. However, if the child
is still found to be an excretors at 6 months, they will be
provided antiviral therapy for poliovirus excretion. This
therapy would be provided to the affected child free of
cost.
The children who test negative for VDPVs or Sabin-like
virus, follow-up stool sample collection will be done after
a year.
Process
In order to maximise the surveillance coverage of
primary immune deficient children, hospital paediatricians will be sufficiently sensitised to the necessary
referral process.
Children with suspected PID screened using JMF
warning signs will be enrolled and the following laboratory investigations would be sent for confirmation
(figure 2).
►► CBC (absolute neutrophil and lymphocyte count).
►► HIV.
►► Flow cytometry (B and T cell markers).
►► QIGs test.
Pethani AS, et al. BMJ Open 2021;11:e045904. doi:10.1136/bmjopen-2020-045904

Patient and public involvement
Considering the nature of the study, it was not possible
to have a priori patient involvement. The country leadership from WHO and National Emergency Operations
Centre were consulted during the study designing to safeguard public interest and safety.
Biological sample collection, transport and laboratory
processing
Blood samples
HIV
For HIV testing, 3–5 mL of whole blood will be collected
in a gel tube and K2-EDTA tube. Gel tube will be used
for serology whereas, EDTA tube would use for PCR.
Samples will be transported to the laboratory at 2°C–8°C.
Initial HIV screening will be performed by chemiluminescent immunoassay using ADVIA Centaur HIV Ag/Ab
Combo assay kit run on ADVIA Centaur XP/CP analyser.
Positive cases will be further confirmed by immunochromatographic antibody detection on Bio-Rad Genius HIV
1/2 assay. In case of indeterminate results or discrepant
results between the above two methods final confirmation will be made by HIV PCR on Xpert HIV-1 Qual Assay
kit and GeneXpert Dx System.
Complete blood count
For CBC, 3–4 mL whole blood sample will be collected in
tubes containing K2 EDTA as an anticoagulant. Samples
3
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Figure 2 Flow diagram of the study process. AKU, Aga Khan University; CBC, complete blood count; ANC, Absolute
Neutrophil Count; ALC, Absolute Lymphocyte Count; KPK, Khyber Pakhtunkhwa; NIH, National Institute of Health.

Flow cytometry
For lymphocyte subset analysis, 3–4 mL of whole blood
will be collected in tubes containing K2 EDTA or sodium
heparin as an anticoagulant. All samples will be transported at 2°C–8°C within 24 hours. Lymphocyte subset

analysis will be performed by flow cytometry using FC500
MCL Flow Cytometer (Beckman Coulter, Miami, Florida,
USA). Monoclonal antibodies against following antigens
were used: T-lineage-associated antigens CD3, CD4 and
lineage antigen CD19 and Natural Killer cell
CD8; B-
antigen CD56.
For CBC and immunoglobulin levels, three different
provided controls (low, normal
levels of manufacturer-
and high) will be run with each batch as an internal
quality control measure. Whereas, for lymphocyte subset
analysis two levels (low and normal) commercial controls
will be used. External proficiency is assured by simultaneously analysing samples from the College of American
Pathologists two times per year for immunoglobulin levels
and three times per year for both CBCs and lymphocyte
subset analysis.
Following samples will be considered unsatisfactory for
analysis: unlabeled or mislabeled samples, identification
mismatch between specimen and requisition slip, haemolysed or clotted samples, wrong collection tube, insufficient specimen quantity, excessive delay in specimen
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will be transported as soon as possible to the stat/main
laboratory. The temperature of 18°C–25°C will be maintained if the expected delivery time is within 8 hours,
whereas 2°C–8°C will be maintained if samples are delivered after 8 hours up to a maximum of 3 days. Samples
will be run on the fully automated Sysmex XN series analysers (Sysmex Japan).
Immunoglobulins
For immunoglobulin measurement, 3–5 mL of whole
blood will be collected in a plain tube or gel tube. Transportation temperature of 18°C–25°C (for 8 hours) and
2°C–8°C after 8 hours to 24 hours will be maintained.
Serum IgA, IgG, IgM will be measured on ADVIA 1800
Chemistry analyser (Siemens Healthcare Diagnostics,
New York, USA).
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transport or improperly transported (ie, not at required
temperature).
Stool sample
Testing of stools for the isolation of poliovirus would be
done according to the standardised protocol used at the
Global Polio Laboratory Network.8 9 Two stool specimens
from the enrolled suspected primary immunodeficient
children will be collected in sufficient quantity (~10 g) 24
hours apart. Then the samples will be shipped to WHO
Regional Reference Laboratory for Polio Eradication
Initiative, Virology Department, NIH-Islamabad, Pakistan
within 48 hours maintaining reverse cold chain along
with patient’s investigation questionnaire (also known
as lab request form). The lab request form indicated
all general information such as demographic details
(patient’s name, age, sex and region), vaccination history
and clinical information. Each sample will be provided a
unique identity code (specimen number).
Samples will then be tested for isolation of specific
serotypes. Stool sample processing will start with the
tissue culture in which specimen will be grown. Second,
the molecular method will be used for the isolation and
identification of poliovirus serotypes. Third, two different
assays of one-
step real-
time reverse transcriptase PCR
(rRT-PCR) will be used for detection of polioviruses using
the protocols and primers/probes corresponding to 5’
UTR and VP1 region. These assays will include Intra-typic
differentiation rRT-PCR that is for the confirmation, serotype identification and characterisation for polioviruses.
However, rRT-PCR will be used for VDPV screening for
VDPVs screening. Testing will be done according to the
WHO guidelines for the identification of poliovirus.
Data management and quality assurance
Data monitoring
Regular supervision for the identification of PID children
at the selected surveillance hospital all over Pakistan will
be done by the iVDPV Working Group members (WGM).
From each hospital, there would be two designated
members who would be comprehensively trained on
Jeffrey Modell Signs and identification of primary immunodeficiency by the study PI. These members will be
held responsible for correct identification of JMF signs,
reviewing the filled surveillance questionnaire to ensure
that it is filled properly and training the postgraduate
students, residents and fellows on fundamentals of the
project. Moreover, the project PI and RC of the study will
also review forms and make visits to monitor the surveillance activity and to guide the iVDPV-WGM whenever
required. This iVDPV-WGM will also update RC about the
daily progress of the study via phone calls or by sending a
medical history summary report of suspected PIDs on the
WhatsApp group generated for this study.
Quality of data collection will be ensured by proper
training of the iVDPV-WGM. Quality will also be ensured
through supervision and reviewing of the data collected
by the PI. Moreover, skype/zoom meetings will be
Pethani AS, et al. BMJ Open 2021;11:e045904. doi:10.1136/bmjopen-2020-045904

arranged to maintain coordination among the members
of the team and to keep the members up-to-date and to
resolve any coordination-related issues.
Data editing
Data editing will be done in two phases: field site editing
and office-based editing. Field editing will be done by the
designated member of the surveillance site where they
will check each questionnaire filled by attending physician on the hard copy of the questionnaire at the time of
enrolment. These members will send the questionnaire
to study RC for quality control and would be responsible
for reviewing/editing if required at the central office-Aga
Khan University, Karachi-Pakistan campus.
Data entry and cleaning
Two data entry operators will enter the data into a
data entry application in parallel. Data entered will be
compared for entry errors and the identified errors will
be corrected. The hard copies of surveillance questionnaire will be kept at the secure location until the project
is being completed.
Plan of analysis and sample size
Data will be analysed using STATA V.11. Descriptive
data analysis will be performed by calculating frequency
with percentages for categorical data and mean with SD
or median with IQRs for continuous scale data. We will
calculate hospital-based proportions of total iVDPV cases
in 2-year period. For sensitivity and specificity of the JMF
signs, we will calculate the receiver operating characteristics curve by comparing the results based on screening
with JMF signs with the results of flow cytometry and QIG
tests. Since this is a surveillance, sample size calculation
in not obligatory. However, for the sensitivity and specificity of JMF signs a minimum sample size of 50 PID cases,
with 5% level of significance, change in sensitivity from
0.5 to 0.7 using two-sided binomial test and 78% power
to detect a change in specificity from 0.5 to 0.7 using two-
sided binomial test.7
Limitations and strategies to overcome
As PID is a rare condition and many children die before
formal diagnosis, we may not be able to achieve the
required sample size of 50 PID cases in 2-year duration.
While the minimum sample size is not a requirement for
the surveillance objective, it is needed for the calculation
of sensitivity and specificity of the JMF 10 warning signs.
To achieve sufficient sample size, the PI of the project
will review the enrolment data quarterly and may decide
to expand the sentinel sites to other tertiary care hospitals centres in the country to increase the number of
enrolments.
Ethics and dissemination
Ethical approval
The surveillance project has been initiated after the
formal ethical approval granted by the WHO, Aga Khan
5
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University, National Bioethics Committee and Departmental Heads of Paediatrics from each participatory
hospital.
Informed consent
The formal written consent is taken from the parents or
guardians of children with PID before the enrolment for
blood and stool samples. Study details and processes are
explained in detail, thumb impression is taken instead of
a signature for parents who would be unable to read and
write. Furthermore, it is recognised that no additional risk
is involved as the blood collection for diagnostic testing is
standard of care, and the stool collection poses no risks.
For HIV testing, we offer pre and post-test counselling
to the families. If the test comes out positive, a referral will
be made to the nearest National Aids Control programme
for free treatment and follow-ups.
Privacy and confidentiality
The information from the participants will be taken by
maintaining privacy and confidentiality. A unique ID will
be issued to each participant based on the province and
hospital so that the names of any participant might not be
disclosed. For maintaining participant’s confidentiality,
all data forms, reports, and other records will be identified by the same unique identifier. All records will be kept
in a secure location and will be shared only with those
who will be directly involved in the study such as PI and
the coordination team members at AKU and WHO. All
the computerised entries will be done with unique ID’s
only.
Timeframe
This is a 2-year project to commence after approval of
Ethical Review Committee (ERC).
Dissemination plan
The scientific paper resulting from this work will be
submitted for the publication to peer-reviewed journal.
This is the main study protocol paper which serves to
inform about the design, methodology and coordination of the project. Once the surveillance is completed,
study results will be published as a separate scientific
paper. Abstracts would be submitted at relevant conferences, if selected will be presented in the form of poster
or presentation. Study participants will be informed
about the stool sample results as soon as it is available
and shared by the NIH. In case of positive results for
VDPV, parents will be told about further steps. A dissemination seminar will be conducted for the members of
iVDPV working group, WHO, policymakers, paediatric
consultants and fellow researchers with same domain
interest.

6

Way forward
Pakistan National Registry of Primary Immunodeficiency
disease will be developed. The aim of the national PID
registry will be to establish the epidemiological data of
primary immunodeficiency. Moreover, the registry would
serve as a database for the coordination cells on PID in
Pakistan.
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